AR has also been shown to facilitate ER chromatin binding and AR inhibition reduced estradiol-mediated proliferation in ER+/AR+ breast cancer cell lines and synergized with tamoxifen and fulvestrant (85). Here, ESR1 is linked to breast carcinoma.